Gut Microbiome Can Influence Response to PD-1 Blockade in Melanoma
November 10th 2017For patients with metastatic melanoma in particular, immune checkpoint inhibitors were a great advancement in therapeutics. Since then, investigators have focused on ways to improve on treatment with these agents, and one potential method is through manipulation of the gut microbiome.
Read More
The Tumor Microenvironment Mediates Immunotherapy Response
November 10th 2017The tumor microenvironment consists of malignant and nontransformed cells and the associations between them. Nonmalignant cells exhibit tumor-promoting functions during all stages of carcinogenesis. Targeting nonmalignant cells and/or communication mediators may have immunotherapeutic application across various tumor types and could complement other therapies as well.
Read More
Better Computing Devices Are on the Way
November 10th 2017Today, oncologists and their patients face disruptive changes in healthcare practice, medical research, governmental oversight and regulation, business practices, and physician –patient communication—changes brought on by the growth and merging of the fields of information technology, medical technology, medical practice, biology, and physics.
Read More
Evolving Paradigm of Gastrointestinal Cancers
November 10th 2017John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the evolving paradigm of gastrointestinal cancers.
Watch
Improved Understanding of JAK2 Inhibition in Polycythemia Vera
November 9th 2017John O. Mascarenhas, MD, associate professor of medicine, Icahn School of Medicine at Mount Sinai Hospital, discusses the optimal use of ruxolitinib (Jakafi) and the improved understanding of JAK2 inhibition of polycythemia vera.
Watch
Effective Management of CINV Improves Response to Treatment
November 9th 2017The goal of selecting optimal antiemetic therapy continues to be a moving target with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of chemotherapy-induced nausea and vomiting.
Read More
CLL in the Era of Targeted Therapies
November 9th 2017Over the past few years, remarkable advances have been achieved in the field of CLL by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival. These developments have been achieved by a better understanding of the underlying biology and the disease process.
Read More
Combination Checkpoint Therapy Gains Ground in AML and MDS
November 9th 2017Checkpoint-based immune therapies have revolutionized the therapy of solid tumors by achieving breakthrough improvements in melanoma, lung cancer, renal cancer, bladder cancers, and head and neck tumors, among others.
Read More
Long-Term Benefit Maintained Across Subgroups of Melanoma With Dabrafenib/Trametinib Combo
October 22nd 2017Adjuvant treatment with a combination of dabrafenib (Tafinlar) and trametinib (Mekinist) continues to show a long-term survival benefit in patients with melanoma, even across subgroup populations, according to a presentation at the 2017 World Congress of Melanoma (WCM).
Read More
Emerging Therapies, Biologic Discoveries, and Improved QoL on Horizon for NETs
October 21st 2017The treatment armamentarium of neuroendocrine tumors (NETs) is expanding to potentially include novel systemic therapies, a refined understanding of genetic changes in patients with pancreatic NETs, and improvements in surgical timing and quality of life (QoL), according to Diane Reidy Lagunes, MD.
Read More
Nivolumab/Ipilimumab Combination Shows Promise for Melanoma Brain Mets
October 21st 2017According to updated results from the phase II ABC trial presented at the 2017 World Congress of Melanoma, Nivolumab (Opdivo) combined with ipilimumab (Yervoy) showed activity in asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.
Read More
Melanoma Research Now Focusing on Novel Combinations, Biomarkers
October 21st 2017While immunotherapty has led a transformation for melanoma care, combinations of anti–PD-1 and CTLA-4 agents are toxic, and biomarkers are not yet available to help personalize treatment. Therefore, Carolina Robert, MD, PhD, says, further research is needed to explore less toxic, more effective options.
Read More
Jennifer Eads, MD, assistant professor of medicine, senior clinical instructor of medicine, University Hospitals Cleveland Medical Center, discusses the difficulties in diagnosing G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), and the varying treatment approaches for these subsets of patients.
Watch
Pilot Study of Engineered TILs Shows Early Responses in Advanced Melanoma
October 21st 2017In a small phase I study, engineered tumor-infiltrating lymphocytes demonstrated signs of antitumor activity in patients with metastatic melanoma following treatment with a prior checkpoint inhibitor. Results of the pilot study of TILs that were engineered to express transforming growth factor-β dominant negative receptor and nerve growth factor receptor were presented during the 2017 World Congress of Melanoma.
Read More
Immunotherapy/Targeted Therapy Combinations Show Promise in BRAF-Mutated Melanoma
October 21st 2017Triplet therapy with the combination of anti–PD-1/PD-L1 therapy, BRAF, and MEK inhibitors have already shown promise for patients with <em>BRAF</em>-positive advanced melanoma, and the potential for these combinations are increasing, according to Antoni Ribas, MD, PhD.
Read More
Call to Action for Patient-Reported Outcome Measurements in Clinical Practice for NETs Patients
October 21st 2017In a call to action to the neuroendocrine tumor clinical community during the 10th Annual NANETS Symposium, presenter Lesley Moody, MBA, addressed the importance of patient-reported outcomes and patient-reported outcome measurements in the everyday care of patients with NETs, beyond clinical trials.
Read More
Phase III Trial Needed to Confirm Clinical Benefit of Cabozantinib in Carcinoid and Pancreatic NETs
October 20th 2017Encouraging results are being seen following the administration of cabozantinib (Cabometyx) in patients with carcinoid and pancreatic neuroendocrine tumors. Clinical benefit of the drug has been exhibited in patients enrolled in a prospective phase II trial, which was initiated in July 2012; however, a randomized phase III trial will be necessary for confirmation.
Read More
Intralesional Therapy Combinations Improve Responses Over Monotherapy in Melanoma
October 20th 2017In patients with melanoma, the use of intralesional therapies in combination with checkpoint inhibitors has demonstrated to be an improvement to monotherapy and combinations with immunotherapy, according to a presentation by Robert Andtbacka, MD, at the 2017 World Congress of Melanoma.
Read More
Managing Diarrhea in Patients With Carcinoid Syndrome
October 20th 2017Pamela L. Kunz, MD, assistant professor of medicine (oncology), Stanford University Medical Center, discusses managing the adverse event of diarrhea in patients with carcinoid syndrome, specifically with the use of telotristat ethyl (Xermelo) during the 10th Annual NANETS Symposium.
Watch
Challenges in Creating a Multidisciplinary Practice for Patients With NETs
October 20th 2017Bringing coordinated multidisciplinary cancer treatment together into one place is ideal to improve care for patients with neuroendocrine tumors (NETs), according to David C. Metz, MD, during the 10th Annual NANETS Symposium.
Read More